162401-30-1

Basic information

• Product Name: N-(3,5-Dichloro-4-pyridinyl)-3,4-bis(difluoroMethoxy)benzaMide
• Synonyms: 3,4-Bis(difluoroMethoxy) RofluMilast;N-(3,5-Dichloro-4-pyridinyl)-3,4-bis(difluoroMethoxy)benzaMide;BenzaMide, N-(3,5-dichloro-4-pyridinyl)-3,4-bis(difluoroMethoxy)-;N-(3,5-dichloropyridin-4-yl)-3,4-bis(difluoroMethoxy)benzaMide;RofluMilast IMpurity 2;Roflumilast Impurity H
• CAS NO: 162401-30-1
• Molecular Formula: C14H8Cl2F4N2O3
• Molecular Weight: 399.1245328
• Product Categories: Imidazolines/Imidazolidines ,Imidazoles
• Mol File: 162401-30-1.mol

Chemical Properties

• Boiling Point: 377.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.559±0.06 g/cm3(Predicted)
• PKA: 9.62±0.70(Predicted)
• CAS DataBase Reference: N-(3,5-Dichloro-4-pyridinyl)-3,4-bis(difluoroMethoxy)benzaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3,5-Dichloro-4-pyridinyl)-3,4-bis(difluoroMethoxy)benzaMide(162401-30-1)
• EPA Substance Registry System: N-(3,5-Dichloro-4-pyridinyl)-3,4-bis(difluoroMethoxy)benzaMide(162401-30-1)

Safety Data

• Hazardous Substances Data: 162401-30-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-(3,5-Dichloro-4-pyridinyl)-3,4-bis(difluoroMethoxy)benzaMide is used as an impurity in the production of the anti-asthmatic drug Roflumilast (R639700) for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. Its presence in the drug manufacturing process is crucial for quality control and ensuring the safety and efficacy of the final product.
In the pharmaceutical industry, the identification and control of impurities like 3,4-Bis(difluoromethoxy) Roflumilast are essential to maintain the desired therapeutic effects of the drug and minimize any potential adverse effects. N-(3,5-Dichloro-4-pyridinyl)-3,4-bis(difluoroMethoxy)benzaMide serves as a case study for the importance of impurity profiling and management in drug development and production.

Relevant articles and documents

Production and preparation method of roflumilast crystalline powder bulk drug

The invention discloses a production and preparation method of a roflumilast crystalline powder bulk drug. The method comprises the following steps of: 1) acylation reaction: dropwise adding thionyl chloride into a toluene solution of 3-cyclopropylmethoxy-4-difluoromethoxybenzoic acid, and heating the reaction mixture to reflux, carrying out reaction for 2h, then conducting reduced pressure concentration to remove the solvent, dissolving the residue left by concentration in tetrahydrofuran, controlling the temperature of the solution at 15-20DEG C under stirring and dropwise adding the solution into a tetrahydrofuran solution of 4-amino-3, 5-dichloropyridine and sodium hydride; and 2) refining. The method has the beneficial effects that: a commercially available starting material of 1 (3-cyclopropylmethoxy-4-difluoromethoxybenzoic acid) and a starting material of 2 (4-amino-3, 5-dichloropyridine) are selected as the starting materials, acylation and refining are carried out to obtain roflumilast, the process is stable, the yield is high, and industrial production is easy.

FLUOROALKOXY-SUBSTITUTED BENZAMIDES AND THEIR USE AS CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS

Compounds of formula (I), in which one of the substituents R1 or R2 stands for hydrogen, 1-6C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, benzyloxy or totally or partially fluorine-substituted 1-4C-alkoxy, and the other stands for totally or partially fluorine-substituted 1-4C-alkoxy, and R3 stands for phenyl, pyridyl, R31, R32 and R33-substituted phenyl or R34, R35, R36 and R37-substituted pyridyl, in which R31 stands for hydroxy, halogen, cyano, carboxyl, trifluoromethyl 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, 1-4C-alkylcarbonyloxy, amino, mono- or di-1-4C-atkylamino or 1-4C-alkylcarbonylamino; R32 stands for hydrogen, hydroxy, halogen, amino, trifluoromethyl, 1-4C-alkyl or 1-4C-alkoxy; R33 stands for hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy; R34 stands for hydroxy, halogen, cyano, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl or amino; R35 stands for hydrogen, halogen, amino or 1-4C-alkyl; R36 stands for hydrogen or halogen; and R37 stands for hydrogen or halogen. These compounds constitute new effective bronchotherapeutic drugs